{
    "organizations": [],
    "uuid": "47519212453a124822e8053085e6e54a0d5f7095",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-isofol-positive-feedback-in-scient/brief-isofol-positive-feedback-in-scientific-advice-with-ema-on-candidate-drug-idUSFWN1PY04X",
    "ord_in_thread": 0,
    "title": "BRIEF-Isofol: Positive Feedback In Scientific Advice With EMA On Candidate Drug",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - ISOFOL MEDICAL AB:\n* ISOFOL REPORTS SUCCESSFUL OUTCOME FROM THE SCIENTIFIC ADVICE WITH THE EMA\n* ‍RECEIVED POSITIVE FEEDBACK IN SCIENTIFIC ADVICE FROM EMA ON CANDIDATE DRUG ARFOLITIXORIN FOR TREATMENT OF COLON CANCER​\n* ‍SIGNIFICANT PARAMETERS FOR PIVOTAL PHASE III STUDY HAS BEEN AGREED UPON WITH BOTH EMA AND FDA FOR MAA Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-08T15:17:00.000+02:00",
    "crawled": "2018-02-09T16:37:41.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "isofol",
        "medical",
        "ab",
        "isofol",
        "report",
        "successful",
        "outcome",
        "scientific",
        "advice",
        "ema",
        "positive",
        "feedback",
        "scientific",
        "advice",
        "ema",
        "candidate",
        "drug",
        "arfolitixorin",
        "treatment",
        "colon",
        "parameter",
        "pivotal",
        "phase",
        "iii",
        "study",
        "agreed",
        "upon",
        "ema",
        "fda",
        "maa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}